Evaluation of a Novel Vaccine Based on Siderohpore Receptor Proteins and porins (SRP Technology) for Controlling Klebsiella Mastitis in a Dairy Herd


2016 AABP Annual Meeting



PJ Gorden, MK Kleinhenz, JA Ydstie, L Slinden, and D Burkhardt



Large WI Dairy Farms



Oliveira, et al, 2013, J. Dairy Sci. 96:7538-7549



Klebsiella sp.


- K. pneumoniae most common
- K. oxytoca Occasionally seen.
- Raoultella sp
- Virulence factors:
 - Thick polysaccharide capsule Reduces phagocytosis.
 - LPS Lipopolysaccharide
 - O Ag Prevents complement fixation.




Capsule




Milk Loss



Schukken, et al. 2012, Vet Clin Food Anim 28:239–256



Schukken, et al. 2012, Vet Clin Food Anim 28:239–256





Overview of ISU Dairy

- 429 cows
- 378 milking
- Free stall barn houses all lactating cows with manger headlocks
- Currently bedded with manure solids (not heat treated)
 - Approximately 30% dry matter coming off the separator.
 - Stalls are re-bedded 3x/week.
- J5 Vaccination
 - 4 x/lactation (-45, -28, 25, & 90 DIM)



Klebsiella Cases - Outcome by DIM







AgriLabs® Launches Novel Klebsiella Vaccine

AgriLabs® Launches Novel Klebsiella Vaccine

Klebsiella vaccine with SRP technology is a new management tool for the dairy industry


ST. JOSEPH, Mo., August 6, 2014 — AgriLabs is teaming up with Epitopix to bring a first-of-its kind autogenous Klebsiella mastitis vaccine with SRP technology. With Klebsiella pneumoniae mastitis, cattle production losses and death due to intramammary infection (IMI) are overall higher when compared to E. coli.1 Additionally, the economic impact of this disease can result in a daily milk loss of as much as 15 to 20 pounds. While this can be distressing, dairy producers now have a unique solution to help manage Klebsiella mastitis in their herds.

"We are proud to be partnering with Epitopix to pioneer this unique technology in the dairy industry," said Steve Schram, President and CEO of AgriLabs. "This new vaccine technology will enable us to continue to serve the needs of producers and give them access to a new tool for the management of Klebsiella."




What is SRP® Technology


- Bacteria need iron to grow and it's limited inside the host
- Bacteria use siderophores to steal iron from the host
- Bacteria utilize Siderophore Receptors to transport iron-siderophore complexes through the cell wall.
- SRP® Technology utilizes Siderophore Receptors as the antigen for vaccine Production to stop the ability of the bacteria to acquire iron




SDS-PAGE Showing Effect of Iron Restriction on Protein Expression



MALDI-TOF Identification of Klebsiella pneumoniae Master Seed (Vaccine Composition used in ISU Study)



Conservation of Klebsiella Siderophore Receptor and Porin Proteins Across the United States



Outcomes of Klebsiella Infection

- Recurring infections
- Culling and/or Death 60-80% of cows with Klebsiella mastitis leave the herd within that lactation based on data at ISU dairy in the year prior to the trial. Others in the industry report similar outcomes.




Study Design

- 2 Groups
 - Klebsiella Pneumoniae Bacterial Extract
 - Placebo (minus antigen)
- Whole Herd vaccination to begin study
 - Some exceptions:
 - Cows within 3 weeks of dry cow protocol
 - Cows 2 weeks pre/post calving
- Dry Cow protocol (and heifer enrollment):
 - 217 DCC
 - initiated 1 week after the study began
- Clinical eligibility began 2 weeks after second dose


Randomization

Cows:



Heifers: assigned to treatment with simple randomization function in Microsoft Excel


Serological Response Following Vaccination with Klebsiella Pneumoniae Bacterial Extract Versus Placebo




Mastitis Data Analysis

- Prevalence: Based on whether a cow had Kleb mastitis
 - Cows with mastitis were counted only once even if they had a subsequent case of mastitis.
 - Risk was calculated based the number of <u>cows</u> that contributed milk during their first 90 Days in Milk
- <u>Incidence</u>: Based on the number cases
 - Cases of mastitis were counted as new unless a previous case of mastitis in preceding 14 days.
 - Rate was calculated based on the exposure days (number of days milked)

Klebsiella Mastitis Prevalence From Cows 1-90 Days in Milk




Klebsiella Mastitis Incidence From Cows 1-90 Days in Milk



Prevented Fraction 0.7594; 95% CI: 0.2804 to 0.9195. P=0.0056

Cumulative Cases of Klebsiella Mastitis in Cows 1-90 Days in Milk




Outcomes of Cows with Klebsiella Mastitis During 1-90 DIM

		Number of cows with recurrent Klebsiella mastitis			
	Total Klebsiella mastitis cows	1 recurrence	2 recurrences	3 recurrences	
Placebo	14	2	1	2	
KPBE	4	1	0	0	


Placebo: 5 cows were culled or died before end of lactation from Klebsiella mastitis

KPBE: 2 cows were culled or died before end of lactation from Klebsiella mastitis




Overall 2.002 pound of milk advantage per cow per day. P=0.0000

Average Daily Milk Production Per Cow up to 90 Days In Milk




Distribution of Somatic Cell Counts For Cows 1-90 DIM



Controlling for other variables, treatment with KPBE reduces SCC scores on average 42%. P=0.0000

Percent of Cows 1-90 DIM Over 200,000 SCC



Categorical Analysis of Cows Over 200,000 SCC

	Below 200,000 cells/mL	More than 200,000 cells/mL	Sum
Placebo	194	66	260
KPBE	247	33	280
Sum	441	99	540

Prevented Fraction 0.5357. 95% CI:0.3196 to 0.6832. P=0.0000


Current Situation

- Vaccinated entire herd 2x:
 - April 16' 1.85 lb/day milk drop (3 days before & 3 after)
 - May '16 2.39 lb/d milk drop

• May '14 – April '15 – 56% of cases sold/died.



• May 1 – Sept 1, 16 – 32% of cases sold/died.



"Yes ... I believe there's a question in the back."